Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Roblin

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Science Translational Medicine|June 1, 2012
Seeking validationDavid Roblin
Drug Discovery Today|August 29, 2006
Translational research in the pharmaceutical industry: from bench to bedsideDamian O'Connell, David Roblin
Journal of the American Academy of Dermatology|January 21, 2014
Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severityDavid Roblin, Ro Wickramasinghe, Gil Yosipovitch
Nature Medicine|April 27, 2026
Ten lessons from a decade of scientific translation at the CrickStephen Mayhew, Dave Allen, David Roblin
International Journal of Cardiology|November 7, 2002
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular diseaseHunter C Gillies, David Roblin, Graham Jackson
Drug Discovery Today|May 1, 2007
Translational research in the pharmaceutical industry: from theory to realityStefan R Sultana, David Roblin, Damian O'Connell
Clinical Pharmacology and Therapeutics|January 3, 2024
The Future of Machine Learning Within Target Identification: Causality, Reversibility, and DruggabilityJake P Taylor-King, Michael Bronstein, David Roblin
Acta Dermato-Venereologica|January 17, 2015
Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with PsoriasisDavid Roblin, Gil Yosipovitch, Brent Boyce, et al.
Trials|March 9, 2017
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trialAmy Cranston, Deborah D Stocken, Elaine Stamp, et al.
Future Microbiology|September 19, 2019
Combating resistance while maintaining innovation: the future of antimicrobial stewardshipRichard J Vickers, Matteo Bassetti, Cornelius J Clancy, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Science Translational Medicine|June 1, 2012
Seeking validationDavid Roblin
Drug Discovery Today|August 29, 2006
Translational research in the pharmaceutical industry: from bench to bedsideDamian O'Connell, David Roblin
Journal of the American Academy of Dermatology|January 21, 2014
Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severityDavid Roblin, Ro Wickramasinghe, Gil Yosipovitch
Nature Medicine|April 27, 2026
Ten lessons from a decade of scientific translation at the CrickStephen Mayhew, Dave Allen, David Roblin
International Journal of Cardiology|November 7, 2002
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular diseaseHunter C Gillies, David Roblin, Graham Jackson
Drug Discovery Today|May 1, 2007
Translational research in the pharmaceutical industry: from theory to realityStefan R Sultana, David Roblin, Damian O'Connell
Clinical Pharmacology and Therapeutics|January 3, 2024
The Future of Machine Learning Within Target Identification: Causality, Reversibility, and DruggabilityJake P Taylor-King, Michael Bronstein, David Roblin
Acta Dermato-Venereologica|January 17, 2015
Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with PsoriasisDavid Roblin, Gil Yosipovitch, Brent Boyce, et al.
Trials|March 9, 2017
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trialAmy Cranston, Deborah D Stocken, Elaine Stamp, et al.
Future Microbiology|September 19, 2019
Combating resistance while maintaining innovation: the future of antimicrobial stewardshipRichard J Vickers, Matteo Bassetti, Cornelius J Clancy, et al.
Pageof 2